NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Elranatamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID4026]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

|  |
| --- |
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
| No equality issues have been identified. |

|  |
| --- |
| 1. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
| N/A |

|  |
| --- |
| 1. Has any change to the draft scope been agreed to highlight potential equality issues? |
| No |

|  |
| --- |
| 1. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made? |
| No |

**Approved by Associate Director (name):** …Richard Diaz………………

**Date:** 07 Aug 2023